GeNeuro: Two Studies on ALS published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody
30 Agosto 2022 - 6:06PM
Business Wire
- The first publication confirms the neurotoxic role of
HERV-K/HML-2 ENV detected in the cerebrospinal fluid of sporadic
ALS patients and the preclinical therapeutic effect of GeNeuro’s
anti-HERV-K ENV antibody in neutralizing HERV-K/HML-2 ENV
toxicity.
- The second publication provides a clinically based rationale
for the therapeutic use of a specific neutralizing antibody
addressing sporadic ALS neuropathology, by demonstrating the
positive role of HERV-K ENV-specific but low-abundant natural
autoantibodies on the duration of patients’ survival.
- Sporadic ALS is a devastating disease affecting 10,000 new
patients per year in the U.S. and Europe, with a very limited
survival prognosis.
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a
biopharmaceutical company developing new treatments for
neurodegenerative and autoimmune diseases such as multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe
consequences of COVID-19 (post-COVID), announced today the joint
publications in the leading scientific journal "Annals of
Neurology" of the results of the collaboration between GeNeuro and
the National Institute of Neurological Disorders and Stroke
(NINDS). NINDS is part of the National Institutes of Health (NIH)
of the United States. The two publications describe the novel
pathogenic mechanism of HERV-K in sporadic ALS and confirm the
rationale for the therapeutic relevance of GeNeuro's antibody to
neutralize this neurotoxic protein.
Annals of Neurology is an official journal of the American
Neurological Association. The online publications and their hard
copy version in the last issue of the journal (HERV-K envelope in
spinal fluid of Amyotrophic Lateral Sclerosis is toxic - Steiner et
al, & Antibody response to HML-2 may be protective in
Amyotrophic Lateral Sclerosis - Garcia-Montojo et al. - Annals of
Neurology) present preclinical data showing that HERV-K/HML-2
Envelope protein (HERV-K ENV) is present in the cerebrospinal fluid
(CSF) of sporadic ALS patients, leads to neuronal cell injury and
death, and targets a now identified cellular receptor. The studies
also show that the neurotoxic properties of the HERV-K ENV protein
from ALS patients’ CSF are neutralized by GeNeuro’s anti-HERV-K ENV
antibody and that, in patients with sporadic ALS, higher levels of
autoantibodies targeting the HERV-K ENV protein are associated with
a longer survival.
“Our pre-clinical work on ALS has evidenced that HERV-K ENV
mediates toxicity via three interlinked pathways, leading to
neuronal cell death. GeNeuro’s GN-K01 antibody has demonstrated to
neutralize this effect in pre-clinical in vivo and in vitro
models,” said Dr. Avindra Nath, clinical director at the
National Institute of Neurological Disorders and Stroke. “Our
second publication confirms the rationale for conducting clinical
trials with the anti-HERV-K ENV antibody to address sporadic ALS
neuropathology”.
Dr. Hervé Perron, Scientific Director of GeNeuro, said:
"These publications highlight the results obtained through the
collaboration between the NINDS and GeNeuro. They support and
confirm the relevance of GeNeuro's approach to sporadic ALS via its
novel monoclonal antibody that inhibits the neurotoxic effects of
the HERV-K ENV protein, an endogenous toxin detected in the
cerebrospinal fluid of patients. We now want to move forward as
quickly as possible to provide what could be a prospective
life-changing treatment for patients".
As previously mentioned, GeNeuro's preclinical development
program has confirmed the ability to detect HERV-K ENV in sporadic
ALS patients and has enabled its anti-HERV-K ENV antibody to be
humanized and ready to enter GMP production. The published findings
now open the way for precision medicine with a biomarker-based
clinical approach, administering GeNeuro’s neutralizing antibody
only to sporadic ALS patients who are positive to the HERV-K ENV
protein.
Amyotrophic lateral sclerosis (ALS), often referred to as Lou
Gehrig’s disease, is a rapidly progressing neurodegenerative
disorder characterized by the destruction of motor neurons leading
to progressive muscle paralysis. About 90% of ALS cases occur in
patients with no family history of the disease: these cases are
known as sporadic ALS, and occur randomly. In the remaining 10% of
patients, the disease affects multiple people in the same family
with an inherited genetic cause and is called familial ALS. ALS
affects approximately 50,000 patients worldwide, with about 10,000
new patients per year in the United States and Europe.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It owns rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
Disclaimer: This press release contains certain forward -
looking statements and estimates concerning GeNeuro’s financial
condition, operating results, strategy, projects and future
performance and the markets in which it operates. Such
forward-looking statements and estimates may be identified by
words, such as “anticipate,” “believe,” “can,” “could,” “estimate,”
“expect,” “intend,” “is designed to,” “may,” “might,” “plan,”
“potential,” “predict,” “objective,” “should,” or the negative of
these and similar expressions. They incorporate all topics that are
not historical facts. Forward looking statements, forecasts and
estimates are based on management’s current assumptions and
assessment of risks, uncertainties and other factors, known and
unknown, which were deemed to be reasonable at the time they were
made but which may turn out to be incorrect. Events and outcomes
are difficult to predict and depend on factors beyond the company’s
control. Consequently, the actual results, financial condition,
performances and/or achievements of GeNeuro or of the industry may
turn out to differ materially from the future results, performances
or achievements expressed or implied by these statements, forecasts
and estimates. Owing to these uncertainties, no representation is
made as to the correctness or fairness of these forward-looking
statements, forecasts and estimates. Furthermore, forward-looking
statements, forecasts and estimates speak only as of the date on
which they are made, and GeNeuro undertakes no obligation to update
or revise any of them, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220830005785/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap Louis-Victor Delouvrier / Mathilde Bohin
(investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33 1 44 71 94
98 geneuro@newcap.eu
Grafico Azioni GeNeuro (EU:GNRO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni GeNeuro (EU:GNRO)
Storico
Da Apr 2023 a Apr 2024